Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$65.55

-4.48 (-6.40%)

08:03
10/13/16
10/13
08:03
10/13/16
08:03

bluebird bio says achieved general agreement on regulatory path for TDT

bluebird bio announced it will outline today key activities underway intended to advance the company's LentiGlobin programs in transfusion-dependent beta-thalassemia, or TDT, and severe sickle cell disease, or SCD. The presentation will focus on three key aspects of these activities: 1) potential improvements in transduction efficiency and manufacturing; 2) updates to the protocol for the company's ongoing HGB-206 clinical trial in SCD; and 3) regulatory plans for the company's LentiGlobin drug product candidate in TDT. bluebird bio is working closely with regulatory agencies in the United States and Europe to bring LentiGlobin to patients with TDT who can benefit, as quickly as possible, and has reached general agreement with the U.S. FDA and the European Medicines Agency, respectively, on the regulatory paths forward, the company said. "At bluebird bio we have an incredibly ambitious goal: to deliver one-time, transformative therapies to patients with rare genetic diseases and cancer. We are relentless in our efforts to continue innovating in pursuit of that goal, and we have made substantial advances in the transduction and manufacturing processes, translational research, and clinical development. By incorporating manufacturing Process 2 into our LentiGlobin clinical trials, we believe we can achieve our ultimate goal of increasing hemoglobin production in patients treated with LentiGlobin drug product. In sickle cell disease we have used our early clinical data to identify and implement multiple distinct improvements with the potential to overcome the unique challenges presented by this complex disease. We are hopeful that the tremendous work done by our research and development teams will yield improved outcomes for patients in the clinic in 2017 and beyond, and that the regulatory progress we are making will enable us to bring these treatments to patients as quickly as possible. We anticipate seeing many catalysts across our programs in the next 15 months, including initial clinical data from our Phase 1 clinical study of our bb2121 product candidate in relapsed/refractory multiple myeloma and updates on our Lenti-D program in cerebral adrenoleukodystrophy," said bluebird CEO Nick Leschly.

  • 13

    Oct

  • 06

    Nov

  • 29

    Nov

BLUE bluebird bio
$65.55

-4.48 (-6.40%)

09/15/16
09/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Hold from Sell at Canaccord with analyst Alex Brooks citing valuation. 2. Dick's Sporting (DKS) upgraded to Outperform from Perform at Oppenheimer analyst Brian Nagel citing the potential for better near-term sales trends as "weaker players" in sporting goods retail fail. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying volume trends across the company's commercial portfolio suggests the base business is "on sustainable footing." 4. Petrobras (PBR) upgraded to Neutral from Underperform at Macquarie with analyst Giacomo Romeo saying near-term liquidity is less concerning after recent divestitures, an improved political outlook, and the re-gained access to the bond market. 5. bluebird bio (BLUE) upgraded to Conviction Buy from Buy at Goldman with analyst Salveen Richter saying he expects Gen2 data versus Gen1 data at the October 13 R&D day to show substantial efficacy improvements, which is underappreciated by the Street, a full LentiGlobin update at ASH scheduled for December 3-6, the unveiling of the CAR T/gene editing programs, and two pivotal readouts in mid-17 that will result in a transition to commercial focus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/16
ROTH
09/22/16
INITIATION
Target $87
ROTH
Buy
bluebird bio reinstated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach assumed coverage of bluebird bio with a Buy rating and $87 price target based on a sum-of-parts, probability-adjusted NPV analysis of the company's pipeline. The analyst believes bluebird bio can no longer be considered a fledgling given the clinical success seen in its Lenti-D and Lentiglobin programs, both hatched from the company's versatile core lentiviral technology platform.
09/22/16
09/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Packaging Corp. (PKG) initiated with a Sell at Goldman. 2. Netlist (NLST) initiated with a Buy at B. Riley. 3. Weyerhaeuser (WY) initiated with a Conviction Buy at Goldman. 4. bluebird bio (BLUE) reinstated with a Buy at Roth Capital. 5. Dentsply Sirona (XRAY) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

LYB

LyondellBasell

$80.17

0.16 (0.20%)

06:35
06/26/17
06/26
06:35
06/26/17
06:35
Initiation
LyondellBasell initiated  »

LyondellBasell initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBC

Wabco

$122.63

1.55 (1.28%)

, DDAIF

Daimler AG

$72.99

0.17 (0.23%)

06:34
06/26/17
06/26
06:34
06/26/17
06:34
Hot Stocks
Wabco signs long-term supply agreement with Daimler Trucks »

Holdings (WBC) announced…

WBC

Wabco

$122.63

1.55 (1.28%)

DDAIF

Daimler AG

$72.99

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

MTNB

Matinas BioPharma

$2.77

0.25 (9.92%)

06:33
06/26/17
06/26
06:33
06/26/17
06:33
Conference/Events
Matinas BioPharma to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

EPZM

Epizyme

$14.70

1.05 (7.69%)

, RHHBY

Roche

$32.76

0.46 (1.42%)

06:33
06/26/17
06/26
06:33
06/26/17
06:33
Hot Stocks
Epizyme expands clinical collaboration with Genentech »

Epizyme (EPZM) announced…

EPZM

Epizyme

$14.70

1.05 (7.69%)

RHHBY

Roche

$32.76

0.46 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 13

    Jul

  • 30

    Jul

P

Pandora

$8.28

0.48 (6.15%)

, SIRI

SiriusXM

$5.35

0.11 (2.10%)

06:33
06/26/17
06/26
06:33
06/26/17
06:33
Upgrade
Pandora, SiriusXM rating change  »

Pandora upgraded to…

P

Pandora

$8.28

0.48 (6.15%)

SIRI

SiriusXM

$5.35

0.11 (2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

SVU

Supervalu

$2.94

-0.04 (-1.34%)

06:31
06/26/17
06/26
06:31
06/26/17
06:31
Hot Stocks
Supervalu announces resignation of CFO Bruce Besanko »

Supervalu announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBS

RBS

$6.27

-0.03 (-0.48%)

06:30
06/26/17
06/26
06:30
06/26/17
06:30
Periodicals
RBS to cut 443 jobs in UK, move many of them to India, Reuters says »

Royal Bank of Scotland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GS

Goldman Sachs

$217.19

-2.58 (-1.17%)

, GM

General Motors

$34.20

0.01 (0.03%)

06:27
06/26/17
06/26
06:27
06/26/17
06:27
Periodicals
Goldman's global head of equity capital markets to retire, Bloomberg reports »

Goldman Sachs' (GS)…

GS

Goldman Sachs

$217.19

-2.58 (-1.17%)

GM

General Motors

$34.20

0.01 (0.03%)

SQ

Square

$24.17

-0.11 (-0.45%)

AIG

AIG

$63.02

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 18

    Jul

  • 25

    Jul

  • 03

    Aug

  • 17

    Oct

ALNY

Alnylam

$85.21

1.25 (1.49%)

06:26
06/26/17
06/26
06:26
06/26/17
06:26
Conference/Events
Alnylam to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 06

    Jul

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

06:25
06/26/17
06/26
06:25
06/26/17
06:25
Periodicals
Nest's head of industrial design is leaving to join LVMH, Recode reports »

Rocky Jacob, head of…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

LVMUY

LVMH

$51.86

0.24 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

VC

Visteon

$95.91

1.05 (1.11%)

06:23
06/26/17
06/26
06:23
06/26/17
06:23
Upgrade
Visteon rating change  »

Visteon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$71.21

0.95 (1.35%)

06:22
06/26/17
06/26
06:22
06/26/17
06:22
Periodicals
Microsoft Windows 10 source code leaked, The Register reports »

Microsoft suffered a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 20

    Jul

ENG

ENGlobal

$1.19

0.1 (9.17%)

06:21
06/26/17
06/26
06:21
06/26/17
06:21
Hot Stocks
ENGlobal announces strategic alliance with Coggins International »

ENGlobal Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$32.76

0.46 (1.42%)

06:18
06/26/17
06/26
06:18
06/26/17
06:18
Hot Stocks
Genentech: Emicizumab showed reduction in bleeds across two pivotal studies »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 13

    Jul

  • 30

    Jul

GM

General Motors

$34.20

0.01 (0.03%)

06:17
06/26/17
06/26
06:17
06/26/17
06:17
Periodicals
General Motors settles hundreds of ignition switch lawsuits, Reuters reports »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

ILMN

Illumina

$185.28

2.29 (1.25%)

06:16
06/26/17
06/26
06:16
06/26/17
06:16
Hot Stocks
Genomics England adopts Illumina's BaseSpace variant interpreter for cancer »

Illumina and Genomics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$25.88

-0.04 (-0.15%)

06:15
06/26/17
06/26
06:15
06/26/17
06:15
Hot Stocks
Taked, Biological E. Limited to develop low-cost combination vaccines »

Takeda Pharmaceutical and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOG

Harley-Davidson

$55.54

-0.69 (-1.23%)

, VLKAY

Volkswagen

$30.63

-0.25 (-0.81%)

06:14
06/26/17
06/26
06:14
06/26/17
06:14
Periodicals
Harley-Davidson 'seriously considering bid' for Volkswagen's Ducati, WSJ says »

Harley-Davidson (HOG) is…

HOG

Harley-Davidson

$55.54

-0.69 (-1.23%)

VLKAY

Volkswagen

$30.63

-0.25 (-0.81%)

AUDVF

Audi AG

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 02

    Oct

MMSI

Merit Medical

$37.80

0.7 (1.89%)

06:13
06/26/17
06/26
06:13
06/26/17
06:13
Recommendations
Merit Medical analyst commentary  »

Piper continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

SSNLF

Samsung

, QCOM

Qualcomm

$56.91

0.44 (0.78%)

06:10
06/26/17
06/26
06:10
06/26/17
06:10
Periodicals
Samsung to launch Galaxy Note8 in late September, VentureBeat says »

Samsung (SSNLF) is…

SSNLF

Samsung

QCOM

Qualcomm

$56.91

0.44 (0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ALNY

Alnylam

$85.21

1.25 (1.49%)

06:10
06/26/17
06/26
06:10
06/26/17
06:10
Hot Stocks
Alnylam: Givosian demonstrated decreased annual attack rate in study »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

CS

Credit Suisse

$13.74

-0.07 (-0.51%)

06:09
06/26/17
06/26
06:09
06/26/17
06:09
Initiation
Credit Suisse initiated  »

Credit Suisse resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

IBM

IBM

$154.11

-0.29 (-0.19%)

06:09
06/26/17
06/26
06:09
06/26/17
06:09
Hot Stocks
IBM, AEON to build blockchain-based financial platform for Asian market »

AEON Financial Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

UBS

UBS

$16.06

-0.08 (-0.50%)

06:08
06/26/17
06/26
06:08
06/26/17
06:08
Upgrade
UBS rating change  »

UBS upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MTNB

Matinas BioPharma

$2.77

0.25 (9.92%)

06:07
06/26/17
06/26
06:07
06/26/17
06:07
Hot Stocks
Matinas: Clinical, mycological responses for MAT2203 didn't meet expectations »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.